Clinical trialPhase 2Active not recruiting
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
A Randomized, Placebo-Controlled Trial of Tocotrienol in the Prevention of Pancreatic Intraductal Papillary Mucinous Neoplasm Progression
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 9 July 2024
- Expected end
- September 2026
- Enrollment
- 4 participants
- Sites
- 2
- Primary outcomes
- IPMN Progression Free Survival (iPFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 13 November 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.